{
    "clinical_study": {
        "@rank": "129454", 
        "arm_group": {
            "arm_group_label": "Cobimetinib and itraconazole Arm", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, 2-period, fixed sequence, drug interaction study will investiga te the\n      effect of co-administration of itraconazole on the pharmacokinetics of co bimetinib in\n      healthy volunteers. Volunteers will receive multiple repeating dose s of cobimetinib and\n      itraconazole. The anticipated time on study treatment is ap proximately one month."
        }, 
        "brief_title": "A Study to Evaluate of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Volunteers", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult volunteers\n\n          -  Within BMI range 18.5 to 32 kg/m2, inclusive\n\n          -  Creatine phosphokinase levels must be below 2.5 times the upper limit of normal (ULN)\n             and if elevated, must not be clinically significant\n\n          -  Liver function tests for aspartate aminotransferase, alanine aminotransferase, and\n             alkaline phosphatase must be below 2 times the ULN; bilirubin must be below 1.5 times\n             the ULN; and all liver function test elevations must not be clinically significant\n\n          -  In good health, determined by no clinically significant findings from medical\n             history, 12-lead ECG, and vital signs\n\n          -  Clinical laboratory evaluations within the reference range for the test laboratory,\n             unless deemed not clinically significant by the Investigator\n\n          -  Negative test for selected drugs of abuse at Screening and at each Check-in\n\n          -  Negative hepatitis panel (including HBsAg and anti-HCV) and negative HIV antibody\n             screens\n\n          -  Females must not be pregnant or lactating\n\n          -  Males and females (of child-bearing potential) must use two forms of adequate\n             contraception\n\n        Exclusion Criteria:\n\n          -  Significant history or clinical manifestation of any metabolic, allergic,\n             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,\n             neurological, or psychiatric disorder\n\n          -  History of significant hypersensitivity, intolerance, or allergy to any drug\n             compound, food, or other substance, unless approved by the Investigator\n\n          -  History of stomach or intestinal surgery or resection that would potentially alter\n             absorption and/or excretion of orally administered drugs; except that appendectomy,\n             hernia repair, and/or cholecystectomy will be allowed\n\n          -  History of diabetes mellitus and/or elevated fasting glucose at baseline\n\n          -  History or presence of an abnormal ECG, which, in the Investigator's opinion, is\n             clinically significant\n\n          -  History of alcoholism or drug addiction within 1 year prior to study start\n\n          -  Use of any tobacco- or nicotine-containing products (within 6 months prior to study\n             start and during the entire study\n\n          -  Participation in any other investigational study drug or biologic agent trial in\n             which receipt of an investigational study drug occurred within 5 half-lives or 30\n             days, whichever is longer, or exposure to any biological therapy or investigational\n             biological agent within 90 days prior to study entry and during the entire study from\n             study start to Study Completion, inclusive"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01929876", 
            "org_study_id": "GP28620"
        }, 
        "intervention": [
            {
                "arm_group_label": "Cobimetinib and itraconazole Arm", 
                "description": "Treatment 1: single 10 mg dose of cobimetinib on day 1; Treatment 2: single 20 mg dose of cobimetinib on day 4", 
                "intervention_name": "Cobimetinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Cobimetinib and itraconazole Arm", 
                "description": "Treatment 2: Itraconazole 200 mg once daily from Day 1 to Day 14", 
                "intervention_name": "itraconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Itraconazole", 
                "Hydroxyitraconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75247"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the plasma concentration versus time curve from zero to infinity ( Plasma AUCinf) of cobimetinib  given alone or with Itraconazole", 
            "safety_issue": "No", 
            "time_frame": "Approximately 1 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01929876"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "Approximately 1 month"
        }, 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}